RBF Protein with MA103 Adjuvant Elicited Protective Immunity against Human Respiratory Syncytial Virus in BALB/c Mice. 2023

Qiongqiong Fang, and Hai Li, and Hu Ren, and Lei Cao, and Hongqiao Hu, and Yan Zhang, and Wenbo Xu
Beijing Centers for Disease Control and Preventative Medical Research, Beijing Center for Disease Prevention and Control, China.

The development of a vaccine against human respiratory syncytial virus (HRSV) has been hampered by enhanced respiratory disease due to the Th2-biased immune response. In the present study, MA103 and aluminum phosphate (Adju-Phos) adjuvants were used to verify the immunogenicity of the recombinant fusion (RBF) protein (F protein expressed by Escherichia coli). Both adjuvants significantly increased the neutralizing antibody titer and number of interferon gamma (IFN-γ)-secreting CD4+ T cells in mice. Based on the immunoglobulin G1 (IgG1)/IgG2a and IFN-γ/interleukin 4-secreting CD4+ T cell ratio, however, MA103 significantly enhanced the Th1-biased immune response. The pathological damage to the lung in the RBF/MA103 group was less than what was seen in the RBF/Adju-Phos group. Additionally, the number of HRSV copies in the lungs of the RBF/MA103 group decreased by approximately 3 × log10. These results suggested that MA103 provides better protection against HRSV in mice.

UI MeSH Term Description Entries
D007371 Interferon-gamma The major interferon produced by mitogenically or antigenically stimulated LYMPHOCYTES. It is structurally different from TYPE I INTERFERON and its major activity is immunoregulation. It has been implicated in the expression of CLASS II HISTOCOMPATIBILITY ANTIGENS in cells that do not normally produce them, leading to AUTOIMMUNE DISEASES. Interferon Type II,Interferon, Immune,gamma-Interferon,Interferon, gamma,Type II Interferon,Immune Interferon,Interferon, Type II
D008807 Mice, Inbred BALB C An inbred strain of mouse that is widely used in IMMUNOLOGY studies and cancer research. BALB C Mice, Inbred,BALB C Mouse, Inbred,Inbred BALB C Mice,Inbred BALB C Mouse,Mice, BALB C,Mouse, BALB C,Mouse, Inbred BALB C,BALB C Mice,BALB C Mouse
D011993 Recombinant Fusion Proteins Recombinant proteins produced by the GENETIC TRANSLATION of fused genes formed by the combination of NUCLEIC ACID REGULATORY SEQUENCES of one or more genes with the protein coding sequences of one or more genes. Fusion Proteins, Recombinant,Recombinant Chimeric Protein,Recombinant Fusion Protein,Recombinant Hybrid Protein,Chimeric Proteins, Recombinant,Hybrid Proteins, Recombinant,Recombinant Chimeric Proteins,Recombinant Hybrid Proteins,Chimeric Protein, Recombinant,Fusion Protein, Recombinant,Hybrid Protein, Recombinant,Protein, Recombinant Chimeric,Protein, Recombinant Fusion,Protein, Recombinant Hybrid,Proteins, Recombinant Chimeric,Proteins, Recombinant Fusion,Proteins, Recombinant Hybrid
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000276 Adjuvants, Immunologic Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. Immunoactivators,Immunoadjuvant,Immunoadjuvants,Immunologic Adjuvant,Immunopotentiator,Immunopotentiators,Immunostimulant,Immunostimulants,Adjuvant, Immunologic,Adjuvants, Immunological,Immunologic Adjuvants,Immunological Adjuvant,Adjuvant, Immunological,Immunological Adjuvants
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000914 Antibodies, Viral Immunoglobulins produced in response to VIRAL ANTIGENS. Viral Antibodies
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus
D018113 Respiratory Syncytial Virus, Human The type species of PNEUMOVIRUS and an important cause of lower respiratory disease in infants and young children. It frequently presents with bronchitis and bronchopneumonia and is further characterized by fever, cough, dyspnea, wheezing, and pallor. HRSV Human respiratory syncytial virus,Human respiratory syncytial virus,human RSV,RSV, human,human RSVs

Related Publications

Qiongqiong Fang, and Hai Li, and Hu Ren, and Lei Cao, and Hongqiao Hu, and Yan Zhang, and Wenbo Xu
March 2020, Archives of virology,
Qiongqiong Fang, and Hai Li, and Hu Ren, and Lei Cao, and Hongqiao Hu, and Yan Zhang, and Wenbo Xu
January 2020, Frontiers in immunology,
Qiongqiong Fang, and Hai Li, and Hu Ren, and Lei Cao, and Hongqiao Hu, and Yan Zhang, and Wenbo Xu
December 2012, Journal of virology,
Qiongqiong Fang, and Hai Li, and Hu Ren, and Lei Cao, and Hongqiao Hu, and Yan Zhang, and Wenbo Xu
February 1998, The Journal of infectious diseases,
Qiongqiong Fang, and Hai Li, and Hu Ren, and Lei Cao, and Hongqiao Hu, and Yan Zhang, and Wenbo Xu
January 2018, PloS one,
Qiongqiong Fang, and Hai Li, and Hu Ren, and Lei Cao, and Hongqiao Hu, and Yan Zhang, and Wenbo Xu
April 2014, Antiviral research,
Qiongqiong Fang, and Hai Li, and Hu Ren, and Lei Cao, and Hongqiao Hu, and Yan Zhang, and Wenbo Xu
August 1997, Pediatric research,
Qiongqiong Fang, and Hai Li, and Hu Ren, and Lei Cao, and Hongqiao Hu, and Yan Zhang, and Wenbo Xu
October 1999, Vaccine,
Qiongqiong Fang, and Hai Li, and Hu Ren, and Lei Cao, and Hongqiao Hu, and Yan Zhang, and Wenbo Xu
January 2023, Infection and drug resistance,
Qiongqiong Fang, and Hai Li, and Hu Ren, and Lei Cao, and Hongqiao Hu, and Yan Zhang, and Wenbo Xu
October 2012, Immunity & ageing : I & A,
Copied contents to your clipboard!